Clinically relevant information about cutaneous lupus erythematosus

Archives of Dermatology

Volumn 145, Issue 3, 2009, Pages 316-319

  Callen, Jeffrey P ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CORTICOSTEROID; DOCETAXEL; DOXORUBICIN; HYDROCHLOROTHIAZIDE; HYDROXYCHLOROQUINE; INCYCLINIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

CLINICAL FEATURE; CLINICAL PRACTICE; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG SUBSTITUTION; HUMAN; NOMENCLATURE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SKIN LUPUS ERYTHEMATOSUS; SMOKING CESSATION;

HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; SMOKING;

EID: 62649130181     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2008.582     Document Type: Review

References (28)

1. Ackerman AB, Kerl H, Sanchez J, et al. Lupus erythematosus. In: Guo Y, Hofer A, Kelly P, et al, eds. A Clinical Atlas of 101 Common Skin Diseases. New York, NY: Ardor Scribendi; 2000:326-338.
2. Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol. 1981;4(4):471-475.
3. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271-1277.
4. Durosaro O, Davis MDP, Reed KB, Rohlinger AL. Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study. Arch Dermatol. 2009; 145(3):249-253.
5. Moghadam-Kia S, Chilek K, Gaines E, et al. Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients. Arch Dermatol. 2009;145 (3):255-260.
6. Prystowsky SD, Herndon JH Jr, Gilliam JN. Chronic cutaneous lupus erythem- atosus (DLE): a clinical and laboratory investigation of 80 patients. Medicine (Baltimore). 1976;55(2):183-191.
7. Callen JP. Chronic cutaneous lupus erythematosus: clinical, laboratory, therapeutic, and prognostic examination of 62 patients. Arch Dermatol. 1982;118 (6):412-416.
8. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003; 349(16):1526-1533.
9. James JA, Kim-Howard XR, Bruner BF, et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus. 2007; 16(6):401-409.
10. Shah A, Albrecht J, Bonilla-MartinezZ, et al. Lenalidomide for the treatment of resistant discoid lupus erythematosus. Arch Dermatol. 2009;145(3):303-306.
11. Usmani N, Goodfield M. Efalizumab in the treatment of discoid lupus erythematosus. Arch Dermatol. 2007;143(7):873-877.
12. Kreuter A, Tomi NS, Weiner SM, Huger M, Altmeyer P, GambichlerT. Mycophe- nolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy [published online April 4, 2007]. Br J Dermatol. 2007;156(6): 1321-1327.
13. Reed BR, Huff JC, Jones SK, Orton PW, Lee LA, Norris DA. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med. 1985;103(1):49-51.
14. Callen JP, Kulick KB, Stelzer G, Fowler JF. Subacute cutaneous lupus erythem- atosus: clinical, serologic, and immunogenetic studies of 49 patients seen in a non-referral setting. J Am Acad Dermatol. 1986;15(6):1227-1237.
15. Callen JP, Klein J. Subacute cutaneous lupus erythematosus: clinical, serologic, immunogenetic and therapeutic considerations. Arthritis Rheum. 1988;31(8): 1007-1013.
16. Black DR, Hornung CA, Schneider PD, Callen JP. Frequency and severity of systemic disease in patients with subacute cutaneous lupus erythematosus. Arch Dermatol. 2002;138(9):1175-1178.
17. Fernandes NF, Rosenbach M, Elenitsas R, Kist JM. Subacute cutaneous lupus erythematosus associated with capecitabine monotherapy. Arch Dermatol. 2009; 145(3):340-341.
18. Ghate JV, Turner M, RudekM, et al. Drug-induced lupus associated with COL-3: report of 3 cases. Arch Dermatol. 2001;137(4):471-474.
19. Chen M, Crowson A, Woofter M, Luca M, Magro C. Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases. J Rheumatol. 2004;31(4):818-820.
20. Srivastava M, Rencic A, Diglio G, et al. Drug-induced Ro/SS-A positive cutaneous lupus erythematosus. Arch Dermatol. 2003;139(1):45-49.
21. Callen JP. How frequently are drugs associated with the development or exacerbation of subacute cutaneous lupus? Arch Dermatol. 2003;139(1):89-90.
22. Rahman P, Gladman DD, Urowitz MB. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J Rheumatol. 1998;25(9):1716-1719.
23. Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol. 2000; 42(6):983-987.
24. Koskenmies S, Jarvinen TM, Onkamo P, et al. Clinical and laboratory characteristics of Finnish lupus erythematosus patients with cutaneous manifestations. Lupus. 2008;17(4):337-347.
25. Kreuter A, Galfullina R, Tigges C, et al. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking. Arch Dermatol. 2009;145(3):244-248.
26. Gougerot H, Burnier R. Lupus erythemateux "tumidus." Bull Soc Fr Dermatol Syphiligr. 1930;37:1291-1292.
27. Kuhn A, Richter-Hintz D, Oslislo C, Ruzicka T, Megahed M, Lehmann P. Lupus erythematosus tumidus: a neglected subset of cutaneous lupus erythematosus: report of 40 cases. Arch Dermatol. 2000;136(8):1033-1041.
28. Perez G, Kowalczyk JP, Montie D, Nousari CH. Tumid lupus erythematosus at the site of a scar. Arch Dermatol. 2009;145(3):343-344.